SEO Article Directory Colorado: October 2016

Monday, October 10, 2016

Ponstel

Ponstel is a brand name of mefenamic acid, approved by the FDA in the following formulation(s):

PONSTEL (mefenamic acid - capsule; oral)

Manufacturer: SHIONOGI INC

Approved Prior to Jan 1, 1982

Strength(s): 250MG ^[RLD]^[AB]

Has a generic version of Ponstel been approved?

Yes. The following products are equivalent to Ponstel:

mefenamic acid capsule; oral

Manufacturer: LUPIN LTD

Approval date: July 22, 2011

Strength(s): 250MG ^[AB]

Manufacturer: MICRO LABS LTD

Approval date: November 19, 2010

Strength(s): 250MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ponstel. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ponstel.

Has a generic version of Plan B One-Step been approved?

No. There is currently no therapeutically equivalent version of Plan B One-Step available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plan B One-Step. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plan B One-Step.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

Exclusivity expiration dates:
- July 10, 2012 - NEW PRODUCT

Has a generic version of Plaquenil been approved?

Yes. The following products are equivalent to Plaquenil:

hydroxychloroquine sulfate tablet; oral

Manufacturer: IPCA LABS LTD

Approval date: June 14, 2007

Strength(s): 200MG ^[AB]

Manufacturer: MYLAN

Approval date: May 29, 1998

Strength(s): 200MG ^[AB]

Manufacturer: SANDOZ

Approval date: November 30, 1995

Strength(s): 200MG ^[AB]

Manufacturer: SANDOZ

Approval date: January 27, 1996

Strength(s): 200MG ^[AB]

Manufacturer: TEVA PHARMS

Approval date: September 30, 1994

Strength(s): 200MG ^[AB]

Manufacturer: WATSON LABS

Approval date: November 30, 1995

Strength(s): 200MG ^[AB]

Manufacturer: WEST WARD

Approval date: August 15, 2007

Strength(s): 200MG ^[AB]

Manufacturer: ZYDUS PHARMS USA INC

Approval date: September 21, 2007

Strength(s): 200MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Plaquenil. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Plaquenil.

Has a generic version of Imitrex been approved?

Yes. The following products are equivalent to Imitrex:

sumatriptan succinate injectable; subcutaneous

Manufacturer: APP PHARMS

Approval date: March 2, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: APP PHARMS

Approval date: September 18, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: BEDFORD

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: BEDFORD LABS

Approval date: August 11, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: JHP PHARMS

Approval date: July 9, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: PAR PHARM

Approval date: October 9, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: June 10, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SAGENT STRIDES

Approval date: July 28, 2010

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: SANDOZ

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

Manufacturer: WOCKHARDT

Approval date: February 6, 2009

Strength(s): EQ 6MG BASE/0.5ML (EQ 12MG BASE/ML) ^[AP]

sumatriptan succinate tablet; oral

Manufacturer: AUROBINDO PHARMA

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: DR REDDYS LABS INC

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: November 2, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: ORCHID HLTHCARE

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: RANBAXY

Approval date: February 9, 2009

Strength(s): EQ 100MG BASE ^[AB]

Manufacturer: RANBAXY

Approval date: August 10, 2009

Strength(s): EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: TEVA

Approval date: February 9, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: August 10, 2009

Strength(s): EQ 100MG BASE ^[AB], EQ 25MG BASE ^[AB], EQ 50MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Imitrex. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Imitrex.

Has a generic version of Paremyd been approved?

No. There is currently no therapeutically equivalent version of Paremyd available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Paremyd. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Paremyd.

Has a generic version of Zofran ODT been approved?

A generic version of Zofran ODT has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zofran ODT and have been approved by the FDA:

ondansetron tablet, orally disintegrating; oral

Manufacturer: AUROBINDO PHARMA

Approval date: April 12, 2010

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: BARR

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: GLENMARK GENERICS

Approval date: June 27, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: MYLAN

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: NESHER PHARMS

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: PAR PHARM

Approval date: December 26, 2006

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: RANBAXY

Approval date: February 24, 2011

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: SANDOZ

Approval date: August 13, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: SUN PHARM INDS

Approval date: August 2, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Manufacturer: TEVA

Approval date: June 25, 2007

Strength(s): 4MG ^[AB], 8MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zofran ODT. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Freeze-dried compositions
Patent 5,955,488
Issued: September 21, 1999
Inventor(s): Winterborn; Ian Keith
Assignee(s): Glaxo Wellcome Inc.
The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
Patent expiration dates:
- November 14, 2015
- May 14, 2016
  ✓
  Pediatric exclusivity

Ondansetron freeze-dried dosage form compositions for oral administration
Patent 6,063,802
Issued: May 16, 2000
Inventor(s): Winterborn; Ian Keith
Assignee(s): Glaxco Wellcome Inc.
The invention relates to a freeze-dried dosage form for oral administration capable of being rapidly disintegrated in the mouth comprising ondansetron in the form of its free base or a pharmaceutically acceptable solvate thereof and one or more pharmaceutically acceptable excipients. Methods for the manufacture of such compositions and for their use in the treatment of conditions mediated through the action of 5-hydroxytryptamine (5HT) at 5HT.sub.3 receptors are also described.
Patent expiration dates:
- November 14, 2015
- May 14, 2016
  ✓
  Pediatric exclusivity

Has a generic version of Androderm been approved?

No. There is currently no therapeutically equivalent version of Androderm available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Androderm. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Androderm.

Related Exclusivities

Exclusivity expiration dates:
- October 20, 2014 - NEW STRENGTH

Has a generic version of Helidac been approved?

No. There is currently no therapeutically equivalent version of Helidac available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Helidac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Helidac.

Has a generic version of DynaCirc CR been approved?

No. There is currently no therapeutically equivalent version of DynaCirc CR available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of DynaCirc CR. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with DynaCirc CR.

Has a generic version of Anturol been approved?

No. There is currently no therapeutically equivalent version of Anturol available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Anturol. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Anturol.

Related Exclusivities

Exclusivity expiration dates:
- December 7, 2014 - NEW PRODUCT

Has a generic version of Capoten been approved?

Yes. The following products are equivalent to Capoten:

captopril tablet; oral

Manufacturer: APOTEX

Approval date: October 28, 1998

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: MYLAN

Approval date: February 13, 1996

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: PRINSTON INC

Approval date: February 13, 1996

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: SANDOZ

Approval date: November 9, 1995

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: STASON

Approval date: May 30, 1997

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: TEVA

Approval date: February 13, 1996

Strength(s): 100MG ^[AB], 100MG ^[AB], 12.5MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 25MG ^[AB], 50MG ^[AB], 50MG ^[AB]

Manufacturer: WATSON LABS

Approval date: February 13, 1996

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: WATSON LABS

Approval date: May 23, 1996

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: WEST WARD

Approval date: February 13, 1996

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: WOCKHARDT

Approval date: March 28, 1997

Strength(s): 100MG ^[AB], 12.5MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Capoten. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Capoten.

Has a generic version of Tazorac been approved?

No. There is currently no therapeutically equivalent version of Tazorac available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Tazorac. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Stable gel formulation for topical treatment of skin conditions
Patent 5,914,334
Issued: June 22, 1999
Inventor(s): Charu; Prakash M.
Assignee(s): Allergan, Inc.
The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from the gel to the skin condition.
Patent expiration dates:
- June 7, 2014
  ✓
  Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

Stable gel formulation for topical treatment of skin conditions
Patent 6,258,830
Issued: July 10, 2001
Inventor(s): Charu; Prakash M.
Assignee(s): Allergan Sales, Inc.
The present invention provides a stable gel formulation for topical treatment of skin conditions in humans. The stable gel formulation includes an active agent, having activity for treatment of acne and psoriasis, which is insoluble in water and a plurality of nonaqueous vehicles for both solubilizing said active agent and forming a gel therewith enabling topical application of the gel to a skin condition. The plurality of vehicles are each present in amounts, and in combination, to control release of the active agent from-the gel to the skin condition.
Patent expiration dates:
- June 7, 2014
  ✓
  Patent use: STABLE GEL FORMULATION FOR TOPICAL TREATMENT OF SKIN CONDITIONS

Has a generic version of Agrylin been approved?

Yes. The following products are equivalent to Agrylin:

anagrelide hydrochloride capsule; oral

Manufacturer: ALPHAPHARM

Approval date: June 27, 2006

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: BARR

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: IMPAX LABS

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: IVAX SUB TEVA PHARMS

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: MYLAN

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: SANDOZ

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Manufacturer: WATSON LABS

Approval date: April 18, 2005

Strength(s): EQ 0.5MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Agrylin. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Agrylin.

Has a generic version of ActoPlus Met been approved?

A generic version of ActoPlus Met has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to ActoPlus Met and have been approved by the FDA:

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet; oral)

Manufacturer: MYLAN

Approval date: February 25, 2011

Strength(s): 500MG;EQ 15MG BASE ^[AB], 850MG;EQ 15MG BASE ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of ActoPlus Met. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Pharmaceutical composition
Patent 5,965,584
Issued: October 12, 1999
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Patent expiration dates:
- June 19, 2016
  ✓
  Patent use: AN ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN ADULTS WITH TYPE 2 DIABETES MELLITUS WHO ARE ALREADY TREATED WITH A THIAZOLIDINEDIONE (TZD) AND METFORMIN OR WHO HAVE INADEQUATE GLYCEMIC CONTROL ON A TZD OR METFORMIN ALONE
  ✓
  Drug product

Pharmaceutical composition
Patent 6,166,042
Issued: December 26, 2000
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Patent expiration dates:
- June 19, 2016
  ✓
  Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

Pharmaceutical composition
Patent 6,166,043
Issued: December 26, 2000
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Patent expiration dates:
- June 19, 2016
  ✓
  Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

Pharmaceutical composition
Patent 6,172,090
Issued: January 9, 2001
Inventor(s): Ikeda; Hitoshi & Sohda; Takashi & Odaka; Hiroyuki
Assignee(s): Takeda Chemical Industries, Ltd.
Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for prophylaxis and treatment of diabetes.
Patent expiration dates:
- June 19, 2016
  ✓
  Patent use: ADJUNCT TO DIET AND EXERCISE TO IMPROVE GLYCEMIC CONTROL IN PATIENTS WITH TYPE 2 DIABETES WHO ARE ALREADY TREATED WITH A PIOGLITAZONE AND METFORMIN

Has a generic version of Navelbine been approved?

Yes. The following products are equivalent to Navelbine:

vinorelbine tartrate injectable; injection

Manufacturer: ACTAVIS TOTOWA

Approval date: July 22, 2009

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: APP PHARMS

Approval date: April 18, 2005

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: BAXTER HLTHCARE

Approval date: June 10, 2003

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: BEDFORD

Approval date: December 11, 2003

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: EBEWE PHARMA

Approval date: February 13, 2008

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: HOSPIRA

Approval date: June 2, 2005

Strength(s): EQ 10MG BASE/ML ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: February 3, 2003

Strength(s): EQ 10MG BASE/ML ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Navelbine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Navelbine.

Has a generic version of Aldactone been approved?

Yes. The following products are equivalent to Aldactone:

spironolactone tablet; oral

Manufacturer: ACTAVIS ELIZABETH

Approval date: July 29, 1999

Strength(s): 100MG ^[AB], 50MG ^[AB]

Manufacturer: ACTAVIS ELIZABETH

Approval date: March 15, 2006

Strength(s): 25MG ^[AB]

Manufacturer: AMNEAL PHARMS

Approval date: June 8, 2010

Strength(s): 100MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: July 23, 1986

Strength(s): 25MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: August 11, 1999

Strength(s): 100MG ^[AB], 50MG ^[AB]

Manufacturer: MYLAN

Approval date: August 20, 2001

Strength(s): 100MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Manufacturer: SANDOZ

Approved Prior to Jan 1, 1982

Strength(s): 25MG ^[AB]

Manufacturer: VINTAGE

Approval date: August 29, 2006

Strength(s): 100MG ^[AB], 25MG ^[AB], 50MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Aldactone. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Aldactone.

Has a generic version of Fenoglide been approved?

No. There is currently no therapeutically equivalent version of Fenoglide available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fenoglide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Solid dosage form comprising a fibrate
Patent 7,658,944
Issued: February 9, 2010
Inventor(s): Holm; Per & Norling; Tomas
Assignee(s): LifeCycle Pharma A/S
The invention provides stable, solid dosage forms and pharmaceutical compositions in particulate form comprising a fibrate, for example fenofibrate, dissolved in an non-aqueous vehicle in order to ensure improved bioavailability of the active ingredient upon oral administration relative to known fibrate formulations.
Patent expiration dates:
- December 9, 2024
  ✓
  Drug product

Has a generic version of Zovirax been approved?

Yes. The following products are equivalent to Zovirax:

acyclovir capsule; oral

Manufacturer: APOTEX INC

Approval date: September 28, 2005

Strength(s): 200MG ^[AB]

Manufacturer: DAVA PHARMS INC

Approval date: April 22, 1997

Strength(s): 200MG ^[AB]

Manufacturer: MYLAN

Approval date: April 22, 1997

Strength(s): 200MG ^[AB]

Manufacturer: MYLAN

Approval date: April 13, 1998

Strength(s): 200MG ^[AB]

Manufacturer: RANBAXY

Approval date: September 30, 1998

Strength(s): 200MG ^[AB]

Manufacturer: STASON

Approval date: January 26, 1999

Strength(s): 200MG ^[AB]

Manufacturer: TEVA

Approval date: April 22, 1997

Strength(s): 200MG ^[AB]

Manufacturer: WATSON LABS

Approval date: April 15, 1998

Strength(s): 200MG ^[AB]

acyclovir suspension; oral

Manufacturer: ACTAVIS MID ATLANTIC

Approval date: April 28, 1997

Strength(s): 200MG/5ML ^[AB]

Manufacturer: HI TECH PHARMA

Approval date: June 7, 2005

Strength(s): 200MG/5ML ^[AB]

acyclovir tablet; oral

Manufacturer: APOTEX INC

Approval date: September 29, 2005

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: CARLSBAD

Approval date: April 30, 1999

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: DAVA PHARMS INC

Approval date: November 19, 1997

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: MYLAN

Approval date: April 13, 1998

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: MYLAN

Approval date: September 28, 1998

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: RANBAXY

Approval date: September 30, 1998

Strength(s): 400MG ^[AB], 800MG ^[AB]

Manufacturer: TEVA

Approval date: April 22, 1997

Strength(s): 400MG ^[AB], 800MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zovirax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zovirax.

Has a generic version of Flexeril been approved?

Yes. The following products are equivalent to Flexeril:

cyclobenzaprine hydrochloride tablet; oral

Manufacturer: AUROBINDO PHARMA

Approval date: September 26, 2008

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: INVAGEN PHARMS

Approval date: July 23, 2010

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: JUBILANT CADISTA

Approval date: April 19, 2006

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: KVK TECH

Approval date: February 28, 2011

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: May 23, 1995

Strength(s): 10MG ^[AB]

Manufacturer: MUTUAL PHARM

Approval date: April 6, 2006

Strength(s): 5MG ^[AB]

Manufacturer: MYLAN

Approval date: May 30, 1991

Strength(s): 10MG ^[AB]

Manufacturer: MYLAN

Approval date: February 3, 2006

Strength(s): 5MG ^[AB]

Manufacturer: ORIT LABS LLC

Approval date: April 18, 2008

Strength(s): 10MG ^[AB]

Manufacturer: PLIVA

Approval date: September 29, 1995

Strength(s): 10MG ^[AB]

Manufacturer: PROSAM LABS

Approval date: October 4, 2005

Strength(s): 10MG ^[AB]

Manufacturer: PROSAM LABS

Approval date: February 3, 2006

Strength(s): 5MG ^[AB]

Manufacturer: RANBAXY

Approval date: May 12, 2008

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: SANDOZ

Approval date: November 19, 1991

Strength(s): 10MG ^[AB]

Manufacturer: SANDOZ

Approval date: February 3, 2006

Strength(s): 5MG ^[AB]

Manufacturer: VINTAGE PHARMS

Approval date: February 28, 2007

Strength(s): 10MG ^[AB], 5MG ^[AB]

Manufacturer: WATSON LABS

Approval date: May 3, 1989

Strength(s): 10MG ^[AB]

Manufacturer: WATSON LABS

Approval date: February 3, 2006

Strength(s): 5MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flexeril. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Flexeril.

Has a generic version of Fiorinal been approved?

Yes. The following products are equivalent to Fiorinal:

LANORINAL (aspirin; butalbital; caffeine capsule; oral)

Manufacturer: LANNETT

Approval date: October 11, 1985

Strength(s): 325MG;50MG;40MG ^[AA]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fiorinal. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fiorinal.

Has a generic version of Flumadine been approved?

Yes. The following products are equivalent to Flumadine:

rimantadine hydrochloride tablet; oral

Manufacturer: COREPHARMA

Approval date: November 2, 2001

Strength(s): 100MG ^[AB]

Manufacturer: IMPAX LABS

Approval date: August 30, 2002

Strength(s): 100MG ^[AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Flumadine. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Flumadine.

Has a generic version of Fludara been approved?

Yes. The following products are equivalent to Fludara:

fludarabine phosphate injectable; injection

Manufacturer: ACTAVIS TOTOWA

Approval date: February 11, 2009

Strength(s): 50MG/VIAL ^[AP]

Manufacturer: APP PHARMS

Approval date: October 15, 2007

Strength(s): 50MG/VIAL ^[AP]

Manufacturer: HOSPIRA

Approval date: April 6, 2007

Strength(s): 50MG/VIAL ^[AP]

Manufacturer: TEVA PARENTERAL

Approval date: August 28, 2003

Strength(s): 50MG/VIAL ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Fludara. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Fludara.

Has a generic version of Zorbtive been approved?

No. There is currently no therapeutically equivalent version of Zorbtive available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zorbtive. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Method for enhancing gut absorption
Patent 5,288,703
Issued: February 22, 1994
Inventor(s): Wilmore; Douglas
Assignee(s): Brigham and Women's Hospital
The present invention provides a method for enhancing the gut absorption in a mammal. Specifically, gut absorption in a mammal can be enhanced by the administration of glutamine, or glutamine equivalent, in combination with one or more agents, said agents selected from the group consisting of growth hormone (GH), an agent capable of enhancing endogenous GH production, insulin like growth factor 1 (IGF-1), or an agent capable of enhancing endogenous IGF-1 production.
Patent expiration dates:
- October 7, 2011
  ✓
  Patent use: USE OF GLUTAMINE TOGETHER WITH GROWTH HORMONE FOR THE TREATMENT OF PATIENTS WITH SHORT BOWEL SYNDROME

hGH containing pharmaceutical compositions
Patent 5,898,030
Issued: April 27, 1999
Inventor(s): Samaritani; Fabrizio
Assignee(s): Applied Research Systems Ars Holding N.V
Pharmaceutical compositions containing hGH stabilized by means of saccharose. The formulation is particularly suitable for stabilizing a lyophilisate of recombinant hGH.
Patent expiration dates:
- April 27, 2016
  ✓
  Drug product

Related Exclusivities

Exclusivity expiration dates:
- December 1, 2010 - ORPHAN DRUG EXCLUSIVITY

Friday, October 7, 2016

Ovide

Ovide is a brand name of malathion topical, approved by the FDA in the following formulation(s):

OVIDE (malathion - lotion; topical)

Manufacturer: TARO PHARMS NORTH

Approval date: August 2, 1982

Strength(s): 0.5% ^[RLD]^[AT]

Has a generic version of Ovide been approved?

A generic version of Ovide has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Ovide and have been approved by the FDA:

malathion lotion; topical

Manufacturer: SYNERX PHARMA

Approval date: March 6, 2009

Strength(s): 0.5% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ovide. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Process for preparing malathion for pharmaceutical use
Patent 7,560,445
Issued: July 14, 2009
Inventor(s): Gutman; Daniella & Baidussi; Wael
Assignee(s): Taro Pharmaceuticals North America, Inc.
The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
Patent expiration dates:
- February 1, 2027
  ✓
  Patent use: TREATMENT OF PATIENTS INFECTED WITH PEDICULUS HUMANUS CAPITIS (HEAD LICE AND THEIR OVA) OF THE SCALP HAIR
  ✓
  Drug substance
  ✓
  Drug product

Process for preparing malathion for pharmaceutical use
Patent 7,977,324
Issued: July 12, 2011
Inventor(s): Gutman; Daniella & Baidussi; Wael
Assignee(s): Taro Pharmaceuticals North America, Inc.
The present invention provides a process for preparing a highly pure form of malathion having a reduced level of toxic impurities. In addition, the malathion prepared by the process of this invention is storage stable. The level of toxic impurities in the malathion, e.g., isomalathion, O,O,S-trimethyl phosphorodithioate (MeOOSPS), O,O,S-trimethyl phosphorothioate (MeOOSPO), O,S,S-trimethyl phosphorodithioate (MeOSSPO), malaoxon, isomalathion, diethyl fumarate, methyl malathion, dimethyl malathion, O,O-methyl,ethyl-S-(1,2-dicarboethoxy)ethyl-phosphorodithioate are lower than that of any other commercial preparation of malathion that may be used for pharmaceutical purposes.
Patent expiration dates:
- August 14, 2026
  ✓
  Drug product

Has a generic version of Ocupress been approved?

Yes. The following products are equivalent to Ocupress:

carteolol hydrochloride solution/drops; ophthalmic

Manufacturer: ALCON

Approval date: January 3, 2000

Strength(s): 1% ^[AT]

Manufacturer: BAUSCH AND LOMB

Approval date: January 20, 2000

Strength(s): 1% ^[AT]

Manufacturer: NOVEX

Approval date: February 6, 2002

Strength(s): 1% ^[AT]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Ocupress. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Ocupress.

Has a generic version of Namenda been approved?

No. There is currently no therapeutically equivalent version of Namenda available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Namenda. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

Adamantane derivatives in the prevention and treatment of cerebral ischemia
Patent 5,061,703
Issued: October 29, 1991
Inventor(s): Bormann; Joachim & Gold; Markus R. & Schatton; Wolfgang
Assignee(s): Merz + Co. GmbH & Co.
A method for the prevention and treatment of cerebral ischemia using an adamantane derivative of the formula ##STR1## wherein R.sub.1 and R.sub.2 are identical or different, representing hydrogen or a straight or branched alkyl group of 1 to 6 C atoms or, in conjunction with N, a heterocyclic group with 5 or 6 ring C atoms; wherein R.sub.3 and R.sub.4 are identical or different, being selected from hydrogen, a straight or branched alkyl group of 1 to 6 C atoms, a cycloalkyl group with 5 or 6 C atoms, and phenyl; wherein R.sub.5 is hydrogen or a straight or branched C.sub.1 -C.sub.6 alkyl group, or a pharmaceutically-acceptable salt thereof, is disclosed.
Patent expiration dates:
- April 11, 2015
  ✓
  Patent use: TREATMENT OF MODERATE TO SEVERE DEMENTIA OF THE ALZHEIMER'S TYPE

Monday, October 10, 2016

PONSTEL (mefenamic acid - capsule; oral)

Has a generic version of Ponstel been approved?

mefenamic acid capsule; oral

Related Patents

See also...

PLAN B ONE-STEP (levonorgestrel - tablet; oral)

Has a generic version of Plan B One-Step been approved?

Related Patents

Related Exclusivities

See also...

PLAQUENIL (hydroxychloroquine sulfate - tablet; oral)

Has a generic version of Plaquenil been approved?

hydroxychloroquine sulfate tablet; oral

Related Patents

See also...

IMITREX (sumatriptan succinate - injectable; subcutaneous)

IMITREX (sumatriptan succinate - tablet; oral)

Has a generic version of Imitrex been approved?

sumatriptan succinate injectable; subcutaneous

sumatriptan succinate tablet; oral

Related Patents

See also...

PAREMYD (hydroxyamphetamine hydrobromide; tropicamide - solution/drops; ophthalmic)

Has a generic version of Paremyd been approved?

Related Patents

See also...

ZOFRAN ODT (ondansetron - tablet, orally disintegrating; oral)

Has a generic version of Zofran ODT been approved?

ondansetron tablet, orally disintegrating; oral

Related Patents

See also...

ANDRODERM (testosterone - film, extended release; transdermal)

Has a generic version of Androderm been approved?

Related Patents

Related Exclusivities

See also...

HELIDAC (bismuth subsalicylate; metronidazole; tetracycline hydrochloride - tablet, chewable, tablet, capsule; oral)

Has a generic version of Helidac been approved?

Related Patents

See also...

DYNACIRC CR (isradipine - tablet, extended release; oral)

Has a generic version of DynaCirc CR been approved?

Related Patents

See also...

ANTUROL (oxybutynin - gel, metered; transdermal)

Has a generic version of Anturol been approved?

Related Patents

Related Exclusivities

See also...

CAPOTEN (captopril - tablet; oral)

Has a generic version of Capoten been approved?

captopril tablet; oral

Related Patents

See also...

TAZORAC (tazarotene - cream; topical)

TAZORAC (tazarotene - gel; topical)

Has a generic version of Tazorac been approved?

Related Patents

See also...

AGRYLIN (anagrelide hydrochloride - capsule; oral)

Has a generic version of Agrylin been approved?

anagrelide hydrochloride capsule; oral

Related Patents

See also...

ACTOPLUS MET (metformin hydrochloride; pioglitazone hydrochloride - tablet; oral)

Has a generic version of ActoPlus Met been approved?

PIOGLITAZONE HYDROCHLORIDE AND METFORMIN HYDROCHLORIDE (metformin hydrochloride; pioglitazone hydrochloride tablet; oral)

Related Patents

See also...

NAVELBINE (vinorelbine tartrate - injectable; injection)

Has a generic version of Navelbine been approved?

vinorelbine tartrate injectable; injection

Related Patents

See also...

ALDACTONE (spironolactone - tablet; oral)

Has a generic version of Aldactone been approved?

spironolactone tablet; oral

Related Patents

See also...